A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2008, Vol.14 (17) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 17 |
| container_start_page | |
| container_title | Clinical cancer research |
| container_volume | 14 |
| creator | MCNAMARA, Suzan MILLER, Wilson H PERL, Alexander E SCHUSTER, Stephen J PORTER, David L STADTMAUER, Edward A GOLDSTEIN, Steven C THOMPSON, James E SWIDER, Cezary BAGG, Adam MATO, Anthony R CARROLL, Martin TSAI, Donald E LUGER, Selina M ANDREADIS, Charalambos VOGL, Dan T KEMNER, Allison POTUZAK, Melissa GORADIA, Ami LOREN, Alison W |
| description | |
| format | Article |
| fullrecord | <record><control><sourceid>pascalfrancis</sourceid><recordid>TN_cdi_pascalfrancis_primary_20971321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20971321</sourcerecordid><originalsourceid>FETCH-pascalfrancis_primary_209713213</originalsourceid><addsrcrecordid>eNqNyrFuwjAUQFGrohJQ-g9v6UaQHScNHVPUCqSmqoChW_TkvFBDYke2IzV_TwY-gOme4T6wmUjTLJLxazoZzbN1xBMZT9nc-zPnIhE8mbFzDj9_6Al2cAh9NYCt4Z3-0dlAhpaAsKegjdUKfkcq6oJ1kJ-s0T4sQRv4tiYqJOSqDwTFQI3VFXxRf6FW4wo2tm3JBHTDgj3W2Hh6vvWJvXx-HDfbqEOvsKkdGqV92TndjncZ87dMyFjIe78rq5tJPw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary</title><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>MCNAMARA, Suzan ; MILLER, Wilson H ; PERL, Alexander E ; SCHUSTER, Stephen J ; PORTER, David L ; STADTMAUER, Edward A ; GOLDSTEIN, Steven C ; THOMPSON, James E ; SWIDER, Cezary ; BAGG, Adam ; MATO, Anthony R ; CARROLL, Martin ; TSAI, Donald E ; LUGER, Selina M ; ANDREADIS, Charalambos ; VOGL, Dan T ; KEMNER, Allison ; POTUZAK, Melissa ; GORADIA, Ami ; LOREN, Alison W</creator><creatorcontrib>MCNAMARA, Suzan ; MILLER, Wilson H ; PERL, Alexander E ; SCHUSTER, Stephen J ; PORTER, David L ; STADTMAUER, Edward A ; GOLDSTEIN, Steven C ; THOMPSON, James E ; SWIDER, Cezary ; BAGG, Adam ; MATO, Anthony R ; CARROLL, Martin ; TSAI, Donald E ; LUGER, Selina M ; ANDREADIS, Charalambos ; VOGL, Dan T ; KEMNER, Allison ; POTUZAK, Melissa ; GORADIA, Ami ; LOREN, Alison W</creatorcontrib><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Hematologic and hematopoietic diseases ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Clinical cancer research, 2008, Vol.14 (17)</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20971321$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>MCNAMARA, Suzan</creatorcontrib><creatorcontrib>MILLER, Wilson H</creatorcontrib><creatorcontrib>PERL, Alexander E</creatorcontrib><creatorcontrib>SCHUSTER, Stephen J</creatorcontrib><creatorcontrib>PORTER, David L</creatorcontrib><creatorcontrib>STADTMAUER, Edward A</creatorcontrib><creatorcontrib>GOLDSTEIN, Steven C</creatorcontrib><creatorcontrib>THOMPSON, James E</creatorcontrib><creatorcontrib>SWIDER, Cezary</creatorcontrib><creatorcontrib>BAGG, Adam</creatorcontrib><creatorcontrib>MATO, Anthony R</creatorcontrib><creatorcontrib>CARROLL, Martin</creatorcontrib><creatorcontrib>TSAI, Donald E</creatorcontrib><creatorcontrib>LUGER, Selina M</creatorcontrib><creatorcontrib>ANDREADIS, Charalambos</creatorcontrib><creatorcontrib>VOGL, Dan T</creatorcontrib><creatorcontrib>KEMNER, Allison</creatorcontrib><creatorcontrib>POTUZAK, Melissa</creatorcontrib><creatorcontrib>GORADIA, Ami</creatorcontrib><creatorcontrib>LOREN, Alison W</creatorcontrib><title>A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary</title><title>Clinical cancer research</title><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNyrFuwjAUQFGrohJQ-g9v6UaQHScNHVPUCqSmqoChW_TkvFBDYke2IzV_TwY-gOme4T6wmUjTLJLxazoZzbN1xBMZT9nc-zPnIhE8mbFzDj9_6Al2cAh9NYCt4Z3-0dlAhpaAsKegjdUKfkcq6oJ1kJ-s0T4sQRv4tiYqJOSqDwTFQI3VFXxRf6FW4wo2tm3JBHTDgj3W2Hh6vvWJvXx-HDfbqEOvsKkdGqV92TndjncZ87dMyFjIe78rq5tJPw</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>MCNAMARA, Suzan</creator><creator>MILLER, Wilson H</creator><creator>PERL, Alexander E</creator><creator>SCHUSTER, Stephen J</creator><creator>PORTER, David L</creator><creator>STADTMAUER, Edward A</creator><creator>GOLDSTEIN, Steven C</creator><creator>THOMPSON, James E</creator><creator>SWIDER, Cezary</creator><creator>BAGG, Adam</creator><creator>MATO, Anthony R</creator><creator>CARROLL, Martin</creator><creator>TSAI, Donald E</creator><creator>LUGER, Selina M</creator><creator>ANDREADIS, Charalambos</creator><creator>VOGL, Dan T</creator><creator>KEMNER, Allison</creator><creator>POTUZAK, Melissa</creator><creator>GORADIA, Ami</creator><creator>LOREN, Alison W</creator><general>American Association for Cancer Research</general><scope>IQODW</scope></search><sort><creationdate>2008</creationdate><title>A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary</title><author>MCNAMARA, Suzan ; MILLER, Wilson H ; PERL, Alexander E ; SCHUSTER, Stephen J ; PORTER, David L ; STADTMAUER, Edward A ; GOLDSTEIN, Steven C ; THOMPSON, James E ; SWIDER, Cezary ; BAGG, Adam ; MATO, Anthony R ; CARROLL, Martin ; TSAI, Donald E ; LUGER, Selina M ; ANDREADIS, Charalambos ; VOGL, Dan T ; KEMNER, Allison ; POTUZAK, Melissa ; GORADIA, Ami ; LOREN, Alison W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pascalfrancis_primary_209713213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MCNAMARA, Suzan</creatorcontrib><creatorcontrib>MILLER, Wilson H</creatorcontrib><creatorcontrib>PERL, Alexander E</creatorcontrib><creatorcontrib>SCHUSTER, Stephen J</creatorcontrib><creatorcontrib>PORTER, David L</creatorcontrib><creatorcontrib>STADTMAUER, Edward A</creatorcontrib><creatorcontrib>GOLDSTEIN, Steven C</creatorcontrib><creatorcontrib>THOMPSON, James E</creatorcontrib><creatorcontrib>SWIDER, Cezary</creatorcontrib><creatorcontrib>BAGG, Adam</creatorcontrib><creatorcontrib>MATO, Anthony R</creatorcontrib><creatorcontrib>CARROLL, Martin</creatorcontrib><creatorcontrib>TSAI, Donald E</creatorcontrib><creatorcontrib>LUGER, Selina M</creatorcontrib><creatorcontrib>ANDREADIS, Charalambos</creatorcontrib><creatorcontrib>VOGL, Dan T</creatorcontrib><creatorcontrib>KEMNER, Allison</creatorcontrib><creatorcontrib>POTUZAK, Melissa</creatorcontrib><creatorcontrib>GORADIA, Ami</creatorcontrib><creatorcontrib>LOREN, Alison W</creatorcontrib><collection>Pascal-Francis</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MCNAMARA, Suzan</au><au>MILLER, Wilson H</au><au>PERL, Alexander E</au><au>SCHUSTER, Stephen J</au><au>PORTER, David L</au><au>STADTMAUER, Edward A</au><au>GOLDSTEIN, Steven C</au><au>THOMPSON, James E</au><au>SWIDER, Cezary</au><au>BAGG, Adam</au><au>MATO, Anthony R</au><au>CARROLL, Martin</au><au>TSAI, Donald E</au><au>LUGER, Selina M</au><au>ANDREADIS, Charalambos</au><au>VOGL, Dan T</au><au>KEMNER, Allison</au><au>POTUZAK, Melissa</au><au>GORADIA, Ami</au><au>LOREN, Alison W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary</atitle><jtitle>Clinical cancer research</jtitle><date>2008</date><risdate>2008</risdate><volume>14</volume><issue>17</issue><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2008, Vol.14 (17) |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_20971321 |
| source | American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antineoplastic agents Biological and medical sciences Hematologic and hematopoietic diseases Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Pharmacology. Drug treatments |
| title | A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A38%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pascalfrancis&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%20I%20Study%20of%20Bexarotene,%20a%20Retinoic%20X%20Receptor%20Agonist,%20in%20Non-M3%20Acute%20Myeloid%20Leukemia.%20Commentary&rft.jtitle=Clinical%20cancer%20research&rft.au=MCNAMARA,%20Suzan&rft.date=2008&rft.volume=14&rft.issue=17&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/&rft_dat=%3Cpascalfrancis%3E20971321%3C/pascalfrancis%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |